0001062993-23-019548.txt : 20231018 0001062993-23-019548.hdr.sgml : 20231018 20231018182208 ACCESSION NUMBER: 0001062993-23-019548 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231016 FILED AS OF DATE: 20231018 DATE AS OF CHANGE: 20231018 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Menold Daniel CENTRAL INDEX KEY: 0001705745 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36500 FILM NUMBER: 231333044 MAIL ADDRESS: STREET 1: C/O CYMABAY THERAPEUTICS, INC. STREET 2: 7575 GATEWAY BLVD., SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc. CENTRAL INDEX KEY: 0001042074 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943103561 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7575 GATEWAY BOULEVARD STREET 2: SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-293-8800 MAIL ADDRESS: STREET 1: 7575 GATEWAY BOULEVARD STREET 2: SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX, INC. DATE OF NAME CHANGE: 20090721 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX INC DATE OF NAME CHANGE: 19970710 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2023-10-16 0001042074 CymaBay Therapeutics, Inc. CBAY 0001705745 Menold Daniel C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BLVD., SUITE 110 NEWARK CA 94560 0 1 0 0 Vice President, Finance 1 Common Stock 2023-10-16 4 M 0 17500 3.45 A 17500 D Common Stock 2023-10-16 4 S 0 0 13.7639 D 0 D Employee Stock Option (right to buy) 3.45 2023-10-16 4 M 0 17500 0 D 2027-05-02 Common Stock 17500 17500 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.65 to $13.98, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares subject to the option became vested and exercisable according to the following schedule: 25% of the shares subject to the option vested on April 27, 2018, and the remaining shares vested in equal monthly installments over the next 36 months. /s/ Paul Quinlan, as attorney-in-fact for Daniel Menold 2023-10-18